Wright G L, Beckett M L, Starling J J, Schellhammer P F, Sieg S M, Ladaga L E, Poleskic S
Cancer Res. 1983 Nov;43(11):5509-16.
The immunoperoxidase technique was used to study the localization and distribution of antigens reactive with two monoclonal antibodies, D83.21 and P6.2, produced against cultured prostate tumor cells, in formalin-fixed, paraffin-embedded histological sections of human tissues. Monoclonal D83.21 reacted with 11 of 19 (58%) primary prostate carcinomas and 1 of 6 (17%) metastatic tumors, whereas monoclonal P6.2 reacted with 14 of 19 (68%) primary and 4 of 6 (67%) metastatic prostate tumors. Neither antibody reacted with five primary prostate tumors and one metastatic prostate tumor. In some tumor cells, the antigens recognized by these monoclonals were localized in either the cytoplasm or cell membrane, while in other tumor cells, both diffuse cytoplasmic and membrane or focal staining patterns were observed. In addition to the variable staining patterns, antigenic heterogeneity was also noted within most prostate tumors examined. Two types of staining variability were observed: (a) tumor cells in one area of the tissue section stained positive, but in another area they did not react with the antibody; and (b) both stained and unstained tumor cells were adjacent to each other. These results would suggest that a panel of monoclonals will be required to detect the different subpopulations of prostate tumor cells. Neither antibody reacted with 6 normal or 12 benign prostate tissues, nor any of a variety of other normal human tissues except for staining of the proximal tubules of normal kidneys. The antigen detected by P6.2 demonstrated a wider tissue distribution being found on bladder, breast, lung, and pancreatic tumors, whereas the antigen recognized by D83.21 was restricted to prostate and bladder carcinomas. These antibodies may have clinical applicability for the identification of prostate tumor cells in biopsy specimens and for immunohistopathological classification of prostate carcinomas.
采用免疫过氧化物酶技术，研究针对培养的前列腺肿瘤细胞产生的两种单克隆抗体D83.21和P6.2所识别的抗原，在人组织经福尔马林固定、石蜡包埋的组织学切片中的定位和分布。单克隆抗体D83.21与19例原发性前列腺癌中的11例（58%）及6例转移性肿瘤中的1例（17%）发生反应，而单克隆抗体P6.2与19例原发性前列腺癌中的14例（68%）及6例转移性前列腺肿瘤中的4例（67%）发生反应。两种抗体均未与5例原发性前列腺肿瘤和1例转移性前列腺肿瘤发生反应。在一些肿瘤细胞中，这些单克隆抗体识别的抗原定位于细胞质或细胞膜，而在其他肿瘤细胞中，则观察到弥漫性细胞质和细胞膜染色或局灶性染色模式。除了可变的染色模式外，在大多数检测的前列腺肿瘤中还发现了抗原异质性。观察到两种类型的染色变异性：（a）组织切片一个区域的肿瘤细胞染色呈阳性，但在另一个区域它们不与抗体反应；（b）染色和未染色的肿瘤细胞彼此相邻。这些结果表明，需要一组单克隆抗体来检测前列腺肿瘤细胞的不同亚群。两种抗体均未与6例正常或12例良性前列腺组织发生反应，除了正常肾脏近端小管染色外，也未与其他多种正常人体组织发生反应。P6.2检测到的抗原显示出更广泛的组织分布，在膀胱、乳腺、肺和胰腺肿瘤中均有发现，而D83.21识别的抗原仅限于前列腺癌和膀胱癌。这些抗体可能在活检标本中鉴定前列腺肿瘤细胞以及前列腺癌的免疫组织病理学分类方面具有临床应用价值。
